新闻发布

礼进生物Lyvgen Biopharma 是开发用于癌症治疗的创新肿瘤免疫激动药物的领导者，今天宣布了艾林奇拜单抗（Exlinkibart、LVGN6051, 4-1BB 新一代激动抗体) 与派姆单抗联合治疗在耐药性非小细胞肺癌、黑色素瘤和胃肠道恶性肿瘤中的 Ib 期剂量扩展，以及 艾林奇拜单抗与安罗替尼联合治疗难治性软组织肉瘤 (STS) 的 Ib/II 期试验的最新临床更新将在即将于 5 月 31 日至 6 月4 日举行的美国临床肿瘤学会 (ASCO) 会议上公布。

 
海报细节信息:

Abstract Title: Efficacy,Safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in
aPhase Ib dose expansion in resistant NSCLC, Melanoma, and GI malignancy.

Author: Adil Daud, Vamsidhar Velcheti, Katherine M. Bever, Warren Allen Chow,Costantine Albany, RalphJ. Hauke, Katy K. Tsai, Michael Jon Chisamore, Jieyi
Wang, C. Hubert Chan, Siqing Fu;University of California-San Francisco, San
Francisco, CA; New York University, Laura and IsaacPerlmutter Cancer Center,
New York, NY; Johns Hopkins University, Baltimore, MD; UCI Health,Orange, CA;
Horizon Oncology & Research Center, Lafayette, IN; Nebraska Cancer
Specialists,Omaha, NE; Helen Diller Family Comprehensive Cancer Center,
University of California SanFrancisco, San Francisco, CA; Merck & Co., Inc.,
Rahway, NJ; Lyvgen Biopharma, Shanghai,China; Department of Investigational
Cancer Therapeutics, The University of Texas MD AndersonCancer Center, Houston,
TX

Session: Poster Session – Developmental Therapeutics—Immunotherapy

Abstract Number: 2575

Poster Bd Number: 54

Abstract Title: An open label,phase 1b/2 trial of LVGN6051 (4-1BB agonisticantibody) combined with anlotinib
for refractory soft tissuesarcoma (STS).

Author: Yan Zhou, Xianan Li, Linqing Li, Peng Zhang, Zhaoming Ye, Binghao Li,Yong Chen, Jian Zhang, Xiaomin Ding, Qunzi Zhang, Qiyuan Tan, Chunhao Zhang,
Zhichang Zhang, Ting Yuan, Weiping Ji, Qingcheng Yang, Yang Dong, Jieyi Wang,
C. Hubert Chan, Haiyan Hu; Shanghai Sixth People's Hospital, Shanghai, China;
Hunan Cancer Hospital, Changsha, China; Henan Cancer Hospital, The Affi liated
Cancer Hospital of Zhengzhou University, Zhengzhou, China; Department of
Orthopedics, the Second Affi liated Hospital of Zhejiang University School of Medicine,
Hangzhou, China; Department of Oncology, Shanghai Medical College, Fudan
University; Department of Musculoskeletal Surgery, Fudan University Shanghai
Cancer Center, Fudan University, Shanghai, China; Department of Medical
oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department
of Orthopedics, Shanghai Jiao Tong University Affi liated Sixth People's
Hospital, Shanghai, China; Lyvgen Biopharma, Shanghai, China; Shanghai Jiao
Tong University Affi liated Sixth People’s Hospital, Shanghai, China

Session: PosterSession – Sarcoma – Soft Tissue Tumors

Abstract Number: 11554

Poster Bd Number: 480

完整摘要将于 2024 年 5 月 23 日星期四美国东部时间下午 5:00 发布。海报内容可于2024 年 6月 4日后通过 Lyvgen 网站留言 (https://www.lyvgen.cn/9)索取 。

关于艾林奇拜单抗（Exlinkibart 、LVGN6051)

艾林奇拜单抗（Exlinkibart 、LVGN6051) 是新一代4-1BB 激动性单克隆抗体，通过选择性结合 Fcγ 受体 IIB的设计，实现在肿瘤微环境中局部强激活4-1BB。艾林奇拜单抗和派姆单抗分别靶向 4-1BB 和 PD-1 的联合治疗方案已被临床证实具有良好耐受性，并且在已对肿瘤免疫产生耐药性的黑色素瘤和非小细胞肺癌患者中取得了持久的客观缓解，包括多例完全缓解病例。艾林奇拜单抗和安罗替尼的联合治疗方案也在难治性软组织肉瘤（STS）患者中产生了令人鼓舞的安全性和有效性数据。艾林奇拜单抗联合特瑞普利单抗和紫杉醇治疗复发/转移性头颈鳞状细胞癌（HNSCC）的II期研究正在中国开展。艾林奇拜单抗有望在2028年申报上市。

有关 艾林奇拜单抗（Exlinkibart，LVGN6051) 试验的更多信息，请访问 www.clinicaltrials.gov，标识符为 NCT04130542、NCT05301764、NCT06378177 和 NCT05075993。

关于礼进生物

礼进生物是一家临床阶段创新生物科技公司，专注于开发新型生物治疗药物和癌症疗法。通过其自主知识产权的 xLinkAb 技术平台，公司已开发出具有肿瘤局部免疫刺激活性的单克隆（新一代4-1BB激动抗体艾林奇拜和CD40激动抗体达尼苏拜）和多特异性抗体（新一代 TCE，TROY-Ig），其中两款领先的激动抗体候选药物正处于中美临床II期开发阶段。